EURL PHARMACIE LOR KEUK : revenue, balance sheet and financial ratios

EURL PHARMACIE LOR KEUK is a French company founded 15 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75013), this company of category PME shows in 2017 a revenue of 1.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EURL PHARMACIE LOR KEUK (SIREN 529541625)
Indicator 2025 2024 2023 2022 2021 2019 2018 2017 2016 2015
Revenue N/C N/C N/C N/C N/C N/C N/C 1 667 774 € 1 574 902 € 1 420 011 €
Net income 80 520 € 100 370 € 142 974 € 136 571 € 140 677 € 289 912 € 215 767 € 192 384 € 188 064 € 120 374 €
EBITDA N/C N/C N/C N/C N/C N/C N/C 210 523 € 204 668 € 149 281 €
Net margin N/C N/C N/C N/C N/C N/C N/C 11.5% 11.9% 8.5%

Revenue and income statement

In 2025, EURL PHARMACIE LOR KEUK generates positive net income of 81 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2025: 120 k€ -> 81 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

80 520 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 161%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

160.744%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

34.281%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

26.5%

Solvency indicators evolution
EURL PHARMACIE LOR KEUK

Sector positioning

Debt ratio
160.74 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average

In 2025, the debt ratio of EURL PHARMACIE LOR KEUK (160.74) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
34.28% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average

In 2025, the financial autonomy of EURL PHARMACIE LOR KEUK (34.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 199.83. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

199.826

Liquidity indicators evolution
EURL PHARMACIE LOR KEUK

Sector positioning

Liquidity ratio
199.83 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good +8 pts over 3 years

In 2025, the liquidity ratio of EURL PHARMACIE LOR KEUK (199.83) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
EURL PHARMACIE LOR KEUK

Positioning of EURL PHARMACIE LOR KEUK in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of EURL PHARMACIE LOR KEUK is estimated at 1 279 069 € (range 867 982€ - 2 007 036€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
867k€ 1279k€ 2007k€
1 279 069 € Range: 867 982€ - 2 007 036€
NAF 5 année 2025

Valuation method used

Net Income Multiple
80 520 € × 15.9x = 1 279 070 €
Range: 867 983€ - 2 007 037€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare EURL PHARMACIE LOR KEUK with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about EURL PHARMACIE LOR KEUK

What is the revenue of EURL PHARMACIE LOR KEUK ?

The revenue of EURL PHARMACIE LOR KEUK in 2017 is 1.7 M€.

Is EURL PHARMACIE LOR KEUK profitable?

Yes, EURL PHARMACIE LOR KEUK generated a net profit of 81 k€ in 2025.

Where is the headquarters of EURL PHARMACIE LOR KEUK ?

The headquarters of EURL PHARMACIE LOR KEUK is located in PARIS (75013), in the department Paris.

Where to find the tax return of EURL PHARMACIE LOR KEUK ?

The tax return of EURL PHARMACIE LOR KEUK is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EURL PHARMACIE LOR KEUK operate?

EURL PHARMACIE LOR KEUK operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.